<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627118</url>
  </required_header>
  <id_info>
    <org_study_id>15-156-3</org_study_id>
    <nct_id>NCT02627118</nct_id>
  </id_info>
  <brief_title>Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H</brief_title>
  <acronym>bisphenol-A</acronym>
  <official_title>Clinical Study To Elucidate The Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR When Compared to a Non-BPA Containing Dialyzer, the Nipro ELISIO-15H</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nipro Medical Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dialysis Clinic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to identify hepatic enzyme and estrogen-dependent biochemical changes
      that occur when dialysis patients are treated with dialyzers known to leach BPA (Bisphenol-A)
      into the blood, such as the commercially available Fresenius F160NR, as compared with the
      same chemical evaluations in patients being treated with the non BPA containing ELISIO-15H
      dialyzer. Evaluations of patient's chemistries will be obtained prior to and after 2 months
      of standard dialysis treatments with each dialyzer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to elucidate any eventual biochemical changes, and in particular,
      the in vivo estrogenic activity of BPA (Bisphenol-A), when BPA is being leached into the
      circulation by the Fresenius Optiflux 160NR dialyzer as opposed to the same biochemical
      changes when there is no BPA being leached, as with the non-BPA containing Nipro Elisio 15H
      Polynephron dialyzer. The estrogen dependent biochemical end points in humans include free
      testosterone, sex hormone binding globulin (SHBG) and thyroid binding globulin (TBG)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 11, 2016</completion_date>
  <primary_completion_date type="Actual">July 11, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPA (Bisphenol-A) LEVELS AND ASSOCIATED CHEMICAL CHANGES WITH 2 DIFFERENT DIALYZERS</measure>
    <time_frame>2 MONTHS OF TREATMENT WITH EACH TYPE OF DIALYZER</time_frame>
    <description>BLOOD SAMPLING OF BPA AND ASSOCIATED CHEMICAL CHANGES AFTER 2 MONTHS OF DIALYSIS WITH EITHER FRESENIUS OPTIFLUX 160NR OR NIPRO ELISIO-15H DIALYZER</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>FRESENIUS OPTIFLUX 160NR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 MONTHS OF DIALYSIS WITH THE FRESENIUS OPTIFLUX 160NR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIPRO ELISIO-15H</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FRESENIUS OPTIFLUX 160NR</intervention_name>
    <description>BLOOD SAMPLING BEFORE AND AFTER 2 MONTHS OF DIALYSIS WITH THE FRESENIUS OPTIFLUX F160NR DIALYZER</description>
    <arm_group_label>FRESENIUS OPTIFLUX 160NR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIPRO ELISIO-15H</intervention_name>
    <description>BLOOD SAMPLING BEFORE AND AFTER 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER</description>
    <arm_group_label>NIPRO ELISIO-15H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male ESRD patients 18 years or older

          -  Stable on hemodialysis for more than 3 months

          -  Stable hematocrit equal to or above 29 %

          -  Stable vascular access

          -  Stable anticoagulation

          -  No active infection

          -  Able to sign informed consent and able to participate in the study

          -  Medically stable

        Exclusion Criteria:

          -  • Participation in another study which may interfere with the planned study

               -  Active infection

               -  Medical conditions which may interfere with the study (unstable cardiac status,
                  chronic liver disease, active hepatitis as defined by elevated liver enzymes)

               -  Females (it is expected that potential changes in estrogenic activity that might
                  be seen in patients exposed to BPA will be modest and would be masked by
                  naturally occurring variability of estrogen activity in women at varying stages
                  of gonadal activity (pre, post-menopausal, different points in menstrual cycle,
                  eventual pregnancy, etc). Thus, limiting study to adult males will maximize the
                  possibility of detecting any changes in estrogenic activity.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre A Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <reference>
    <citation>Murakami K, Ohashi A, Hori H, Hibiya M, Shoji Y, Kunisaki M, Akita M, Yagi A, Sugiyama K, Shimozato S, Ito K, Takahashi H, Takahashi K, Yamamoto K, Kasugai M, Kawamura N, Nakai S, Hasegawa M, Tomita M, Nabeshima K, Hiki Y, Sugiyama S. Accumulation of bisphenol A in hemodialysis patients. Blood Purif. 2007;25(3):290-4. Epub 2007 Jul 2.</citation>
    <PMID>17622711</PMID>
  </reference>
  <reference>
    <citation>Huang X, Huang J, Zhang L, Zhu Y, Li Y. A novel ERα-mediated reporter gene assay for screening estrogenic/antiestrogenic chemicals based on LLC-MK2 cells. Toxicol Mech Methods. 2014 Dec;24(9):627-32. doi: 10.3109/15376516.2014.945107. Epub 2014 Sep 26.</citation>
    <PMID>25045971</PMID>
  </reference>
  <reference>
    <citation>Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology. 2006 Jun;147(6 Suppl):S56-69. Epub 2006 May 11. Review.</citation>
    <PMID>16690810</PMID>
  </reference>
  <reference>
    <citation>Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, Melzer D. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA. 2008 Sep 17;300(11):1303-10. doi: 10.1001/jama.300.11.1303. Epub 2008 Sep 16.</citation>
    <PMID>18799442</PMID>
  </reference>
  <reference>
    <citation>Trasande L, Attina TM, Trachtman H. Bisphenol A exposure is associated with low-grade urinary albumin excretion in children of the United States. Kidney Int. 2013 Apr;83(4):741-8. doi: 10.1038/ki.2012.422. Epub 2013 Jan 9.</citation>
    <PMID>23302717</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>April 8, 2017</last_update_submitted>
  <last_update_submitted_qc>April 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Andre A. Kaplan</investigator_full_name>
    <investigator_title>MEDICAL DIRECTOR UCONN DIALYSIS CENTER</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 4, 2018</submitted>
    <returned>May 4, 2018</returned>
    <submitted>May 11, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

